NCT06361316Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 11 Apr 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- First submitted
- 25 Mar 2024
- Start date
- 8 Apr 2024
- Primary completion date
- 25 Mar 2025
- Lead sponsor
- Kuirong Jiang
- Diseases
- Pancreatic cancer
- NCT number
- NCT06361316
What you commit to
- Study type: Interventional
- Planned participants: 53
- From 8 Apr 2024 to the primary completion date, 25 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
- Patients who cannot eat orally and have gastric emptying disorder after surgery;
Other
- Patients with moderate diarrhea: diarrhea ≥4 times per day; the moderate and severe effluents from stoma increased; Or diarrhea that limits activities of daily living;
Who the study is looking for
- ECOG performance status 0 or 1.
- Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1).
- ECOG performance status 0 or 1.
- Life expectancy of greater than or equal to 6 months.
- Able and willing to provide a written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FirstNanjingMU Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.